CMT-Connect Online Essential Oil Webinar March 8, 2017

by | Feb 2, 2017 | 6 comments

Click image to register! 


Learn more on this topic

Related Blog Posts

The Key Role CMT Patients Play in Research

The Key Role CMT Patients Play in Research

Without your participation, researchers won’t have the essential patient information to develop drugs, gene therapies, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies. In addition, as GRIN grows, we gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies.

Join the conversation

Leave a Comment


  1. Gloria

    I just found this site is there a replay of this webinar. If so will you please email me the link and the upcoming webinars.

    • courtney

      Hi Gloria, We do not have a replay of the webinar. We will have future webinars so check back often.


  2. Cindy Heiderscheit

    I have HNPP. I found out early last year that there’s a Doctor in Tennessee that has been doing research on HNPP and has linked it to CMT. I still have all his research notes that brought he and his colleagues to this conclusion.

    • Toni Moore

      Hi I need to get disability for my CMT and other back issues. How difficult is it to get?

      • Sally

        Best advice…go through a disability advocacy organization not an attorney. I tried on my own for over a year then found an advocacy group that specializes in only helping people get approved. Three months and two Dr appointments later I was approved without any stigmas…actually a very validating process. Their fee was 20% of any back payment but nothing going forward. Well worth it! Best wishes!

      • Don Shaw

        I hired an attorney that specializes in SSDI, between him and w/the help of my Dr. it took approximately 6 months to be approved and receive my 1st check.

        Good Luck.


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news